Soleno Therapeutics Inc [NASDAQ: SLNO] gained 0.51% or 0.44 points to close at $86.65 with a heavy trading volume of 330112 shares.
It opened the trading session at $86.12, the shares rose to $87.01 and dropped to $84.69, the range by which the price of stock traded the whole day. The daily chart for SLNO points out that the company has recorded 91.28% gains over the past six months.
If we look at the average trading volume of 1.02M shares, SLNO reached to a volume of 330112 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Soleno Therapeutics Inc [SLNO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLNO shares is $110.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLNO stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Soleno Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 23, 2025. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on March 05, 2025, representing the official price target for Soleno Therapeutics Inc stock. Previously, the target price had yet another raise to $74, while Stifel analysts kept a Buy rating on SLNO stock.
The Price to Book ratio for the last quarter was 18.10, with the Price to Cash per share for the same quarter was set at 5.75.
Trading performance analysis for SLNO stock
Soleno Therapeutics Inc [SLNO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.13. With this latest performance, SLNO shares gained by 11.97% in over the last four-week period, additionally plugging by 91.28% over the last 6 months – not to mention a rise of 92.77% in the past year of trading.
Soleno Therapeutics Inc [SLNO]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -81.42%, with Return on Assets sitting at -81.42%.
An analysis of Institutional ownership at Soleno Therapeutics Inc [SLNO]
There are presently around $112.43%, or 114.60% of SLNO stock, in the hands of institutional investors. The top three institutional holders of SLNO stocks are: VIVO CAPITAL, LLC with ownership of 7.32 million shares, which is approximately 18.9401%. CARLYLE GROUP INC., holding 4.07 million shares of the stock with an approximate value of $$166.36 million in SLNO stocks shares; and CARLYLE GROUP INC., currently with $$137.14 million in SLNO stock with ownership which is approximately 8.6946%.
